Mark D. Kochenderfer

Author

Sarah Cannon

Also Known As

M. Kochenderfer, M.D. Kochenderfer, Mark D. Kochenderfer, Mark Kochenderfer, Patrick Cobb, William Small

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Sarah Cannon Bristol-Myers Squibb (United States)Nebraska Cancer Specialists Comprehensive Cancer Centers of Nevada Asan Medical Center

About

Mark D. Kochenderfer is an author at Sarah Cannon specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.7K
2	Health Sciences	4	4	609
3	Pathology	4	4	173
4	Pharmacology	4	4	217
5	Immunology	3	3	49

Mark D. Kochenderfer

Publications

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, Journal of Clinical Oncology	2021	122
Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Clinical Genitourinary Cancer	2020	101
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer Antonio Jimeno, Keisuke Shirai, Minsig Choi, Annals of Oncology Ii TrialMedicinePharmacologyPathologyHead And Neck Cancer	2014	98
Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8. Heinz‐Josef Lenz, Aparna R. Parikh, David R. Spigel, Journal of Clinical Oncology Health SciencesMedicineStandard TherapiesPrimary EndpointPharmacology	2022	58
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial Heinz‐Josef Lenz, Aparna R. Parikh, David R. Spigel, Journal for ImmunoTherapy of Cancer	2024	57
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn, Clinical Colorectal Cancer OncologyPhase Ii TrialMedicineMetastatic Colorectal CarcinomaPathology	2016	42
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Joshua J. McFarlane, Mark D. Kochenderfer, Mark R. Olsen, Clinical Genitourinary Cancer	2020	32
A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort. Thomas A. Abrams, Syed Mohammad Ali Kazmi, Ira Winer, Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsColorectal Cancer CohortObjective Response Rate	2022	19

Page 1